Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in Granulomatosis with Polyangiitis: results from a single centre.

dc.contributor.author	Besada, Emilio
dc.contributor.author	Koldingsnes, Wenche
dc.contributor.author	Nossent, Johannes C
dc.date.accessioned	2013-12-16T09:32:46Z
dc.date.available	2013-12-16T09:32:46Z
dc.date.issued	2013
dc.description.abstract	Objective: Rituximab (RTX) is an anti-CD20 antibody used successfully in Granulomatosis with Polyangiitis (GPA) for induction and maintenance of remission. Our study aims to evaluate the long term efficacy and safety of chronic pre-emptive RTX therapy in GPA.	en
dc.identifier.citation	EUVAS Conference, 13.04.2013	en
dc.identifier.cristinID	FRIDAID 1022835
dc.identifier.uri	https://hdl.handle.net/10037/5637
dc.identifier.urn	URN:NBN:no-uit_munin_5339
dc.language.iso	eng	en
dc.publisher	UiT Norges arktiske universitet	en
dc.publisher	UiT The Arctic University of Norway	en
dc.rights.accessRights	openAccess
dc.subject	VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Rheumatology: 759	en
dc.subject	VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Reumatologi: 759	en
dc.title	Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in Granulomatosis with Polyangiitis: results from a single centre.	en
dc.type	Conference object	en
dc.type	Konferansebidrag	en